When Ramin Mousavi, President and CEO of CathWorks, steps onto an LSI stage, he likes to mention that CathWorks was the very first company to present at the very first LSI Emerging Medtech Summit, in 2020. It’s an aside delivered with a smile, and is not so much nostalgic but rather a celebratory reflection backed up by 12+ years of startup peaks and valleys, and a game-changing build-to-buy deal with device industry giant Medtronic. For Mousavi, success in medtech is not about flash or speed. It’s about playing the long game, building deliberately, and earning outcomes through persistence and precision. He has built his career around that philosophy.
One of the most notable portfolio realignments in medtech this year comes from Johnson & Johnson MedTech, as the company prepares to separate its legacy orthopedics unit into a standalone business. The move caps nearly two years of internal restructuring and aligns with a wider industry pattern: leading strategics such as Stryker and Medtronic have been rebalancing their portfolios, spinning off slower-growth or non-core segments to focus resources on high-growth therapeutic markets.
In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $264M in new funding, announce regulatory clearances, enter new partnerships, and much more on the road to LSI USA ‘26 in Dana Point (March 16–20). Received FDA 510(k) clearance for X2™, its next-generation augmented reality (AR) surgical headset for use with the xvision Spine SystemⓇ. Purpose-built for the operating room, X2 enhances visualization, ergonomics, and performance for spine procedures.
In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni announce regulatory wins, achieve clinical milestones, appoint new executives, and much more on the road to LSI USA ‘26 in Dana Point (March 16–20). Received FDA Breakthrough Device Designation for its Enhanced Lithotripsy System (ELS), a minimally invasive platform designed to treat kidney stones without general anesthesia, fluoroscopy, or costly capital equipment. The designation accelerates the company’s path to De Novo submission in 2026 and supports its mission to move kidney stone treatments out of the OR and into more accessible outpatient settings.
LSI Europe ’25 has wrapped, marking the fourth Emerging Medtech Summit in Europe and the 11th globally. Nearly 1,000 industry leaders convened in London, generating thousands of meetings and countless opportunities. In the days since, conversations about deals, partnerships, and future collaborations have already started to surface. This summit is about more than presentations; it is where investors, strategics, and entrepreneurs come together to shape the future of healthcare. With more than 200 startups presenting their technologies, commercial milestones, and fundraising goals, the event spotlighted the breadth of innovation happening across the industry.
In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funding, announce strategic partnerships, achieve clinical milestones, and much more on the road to LSI USA ‘26 in Dana Point (March 16–20). Announced that it entered into a securities purchase agreement worth up to $50M in proceeds, with the agreement expected to result in ~$19M in upfront proceeds. The company plans to use the funds for working capital and general corporate purposes, including the advancement of its clinical and product development activities.
In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funding, achieve clinical and regulatory milestones, and much more on the road to LSI USA ‘26 in Dana Point (March 16–20). Completed enrollment of the FULCRUM-VT pivotal FDA IDE study evaluating its ventricular tachycardia-specific ablation technology, with 208 patients across 20 centers. Adagio’s vCLAS™ Cryoablation System, which uses proprietary ultra-low temperature cryoablation (ULTC) technology, is being evaluated to support FDA pre-market approval for the treatment of monomorphic ventricular tachycardia.
Centese originated inside San Francisco-based medical device incubator TheraNova, where Evan Luxon worked as Partner in new product development. While researching the clinical benefit of an automated urine output monitoring device, a chance conversation with cardiac surgeons sparked a new idea. “They asked us if we could do something similar for chest drains,” Luxon recalled. “Those devices were even harder to manage, played an integral role in highly complex procedures, and hadn’t seen innovation in decades. That was the spark.” TheraNova founder Dan Burnett, MD, introduced Luxon to Randy Preston, an experienced, commercially focused operator with experience in cardiovascular markets. “Evan and I dove in, initially on nights and weekends,” said Preston. “We validated the clinical need, talked with leading surgeons from around the country, and explored whether innovating in this field could make a real impact in the lives of patients and healthcare more broadly.”
Tarek Makansi is no stranger to solving big problems with elegant engineering. With a BS from Cornell and a PhD from UC Berkeley in electrical engineering, he began his career in data storage at IBM, where he rose to executive leadership and eventually served as CTO for IBM’s Venture Capital Group. “I was scouting the world for startup companies for IBM to acquire,” he said. “Then I left after 20 years and started Tempronics, which was sold to a Fortune 500 company.” In 2017, after observing the bulky nature of neuromodulation systems, which typically involve large pacemaker-like implants wired to peripheral nerves, Makansi saw an opportunity to rethink the model entirely. “I noticed that for neuromodulation, people were using a large implant in the chest or the back and running a wire to the nerve,” he explained. “As a professional electrical engineer, I became curious. How much electricity was really needed at the nerve? It turned out that it was a very small amount. So I thought: there must be a way to miniaturize this.”
DeepSight’s beginnings trace back to academic innovation. “DeepSight was founded on the strength of a remarkable technology developed by my co-founder, Dr. Lan Yang, at Washington University in St. Louis,” Sadrzadeh explained. He was introduced to Yang through Gaurav Garg at Wing Venture Capital, who ultimately became the company’s seed investor, board member, and a guiding force. “Together with Anand Chandrasheker, we saw that ultrasound was at a stall point and that we could go beyond these limitations by introducing our novel sensor technology.” The team initially explored diagnostic applications, but their focus quickly shifted. “It became clear that the greatest immediate need, and the greatest opportunity for impact, was in interventional medicine,” Sadrzadeh said. “That realization led us to extend to therapeutic applications, where our technology could meaningfully transform the way procedures are performed.”
LSI Asia 2025 proved to be a catalyst for unveiling the next generation of medical technologies. As global healthcare demands evolve, companies at the forefront of medtech innovation are tackling some of the most pressing challenges across diagnostics, therapeutics, and treatment access. In this blog, we explore five exciting companies from the summit that have garnered attention for their novel solutions and market potential. These companies are advancing technologies that will shape the future of healthcare and address critical gaps in patient care.
In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funds, appoint new executives, announce clinical milestones, receive awards, and much more on the road to LSI Europe ‘25 in London (September 7-11).
